Novo Nordisk's 52% Plunge: Is the Company Fumbling Its Leadership in the $150 Billion Weight Loss Market?

Novo Nordisk's stock has declined over 50% from its mid-2024 high amid concerns about increasing competition in the rapidly growing weight loss drug market, projected to reach $150 billion by 2035. While Novo Nordisk currently holds a dominant 62% share of the GLP-1 agonist market, rivals like Eli Lilly and numerous next-generation drugs are emerging, including oral alternatives; however, the stock's lower valuation, with a P/E ratio down to 20, may already reflect these competitive pressures, presenting a potentially attractive entry point for long-term investors despite inherent risks in the pharmaceutical sector.

Analysis

Novo Nordisk's stock has experienced a significant downturn, falling over 52% from its mid-2024 peak, as investor concerns mount over intensifying competition in the lucrative weight loss drug market, which Morgan Stanley projects could expand from approximately $15 billion last year to $150 billion by 2035. Novo Nordisk currently commands a substantial 62% share of the GLP-1 agonist market with its semaglutide products, Ozempic and Wegovy, but faces a formidable challenge from Eli Lilly, holding 35% market share and advancing its oral GLP-1 agonist, orforglipron, which has shown promising phase 3 results and offers manufacturing advantages as a small-molecule drug. While Novo Nordisk aims for year-end regulatory approval for an oral version of Wegovy and is developing CagriSema, its next-generation injectable has reportedly struggled to differentiate itself significantly in late-stage clinical tests. Despite these competitive pressures and the inherent risks of drug development, highlighted by Pfizer's abandonment of its oral GLP-1 agonist danuglipron due to potential liver injury, the sharp contraction in Novo Nordisk's P/E ratio from approximately 50 to 20 suggests that much of this risk is already priced into the stock. With a current PEG ratio of 1.4 against an analyst-projected 14% annual earnings growth, the valuation appears attractive for an industry leader, implying that current market pessimism may be overdone barring significant unexpected setbacks.

Key Decisions for Investors

• Investors should evaluate Novo Nordisk's current valuation, with its P/E ratio at 20 and PEG ratio at 1.4, as a potentially attractive entry point for long-term exposure, considering the stock's significant price correction may have already accounted for increased competition.
• Closely monitor pivotal developments including the regulatory approval status of Novo Nordisk's oral semaglutide (Wegovy pill) expected by year-end, phase 3 clinical trial outcomes for CagriSema, and the competitive performance of Eli Lilly's orforglipron and other emerging treatments.
• Recognize that while Novo Nordisk's dominant market share faces threats, the projected tenfold growth of the weight loss market to $150 billion by 2035 offers substantial opportunity for multiple key players, and the company's established position warrants careful consideration against the backdrop of industry risks.